PPARG and brain neoplasm: Although the precise molecular basis of the antineoplastic mechanisms of PPARγ agonists is not fully understood, our findings suggest that the clinically used PPARγ agonists may offer new therapies to target BTSCs for the treatment of brain tumours in patients.